Search Videos and More
News
TILs: What Are They and How Are They Used in Cancer Treatment?
Tumor-infiltrating lymphocyte, or TIL, therapy uses a patient’s own immune system T cells to fight cancer.
News
Modified Personalized Cancer Vaccine Generates Powerful Immune Response
Dana-Farber researchers designed a novel formulation and delivery approach for the NeoVax personalized cancer vaccine and observed strong vaccine-specific immune responses in patients with melanoma.
News
Dana-Farber Report Shows Alarming Rise in Many Gastrointestinal Cancers in Young People
Dana-Farber experts report rising rates of colorectal, pancreatic, esophageal, and other less common GI cancers in people under 50 and point to important next steps.
News
Teen with Rare Sarcoma Enjoys Stellar Response on Clinical Trial
Like many teenagers, Isabella (Bella) Snow Fraser, 15, enjoys immersing herself in action role-play games online.
News
Tracing a Career of Unrelenting Discovery
Dr. Ben Ebert's Legacy of Collaborative Research Fuels Innovation at Dana-Farber
News
Dana-Farber Research News 07.01.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from June 1 through June 15.
News
Novel Cancer Screening Test for Veterans Now Being Offered at Dana-Farber Cancer Institute
During their time of service, members of the U.S. Armed Forces face considerable risks while fulfilling their mission and protecting the country. However, a less visible risk to the wellbeing of U.S. military members and veterans is on the rise.
News
Cell Density Speaks Volumes About Cancer Treatment Choices
As powerful as modern cancer medicines are, they don’t work for everyone. What if there were a quick test doctors could perform on an individual person’s cancer to help determine which approved treatment would work best for them?
News
Dana-Farber Research News 06.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from May 16 through May 31.
News
FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer
Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ?1] as determined by an FDA-approved test.
News
Double Negative in Cells Could Undermine PARP Inhibitors
There are two ways to fix things: the quick way and the careful one. In cancer, cells with BRCA1 mutations tend to choose the quick fix, leaving them vulnerable to medicines like PARP inhibitors.
Video
Letrozole + Abemaciclib + Metformin Study Presented by Panos Konstantinopoulos, MD, PhD.
Dr. Panos Konstantinopoulos presented the first study of a triplet therapy combining letrozole, abemaciclib, and metformin in any cancer type.